[go: up one dir, main page]

MX2023010083A - Derivados heterociclicos como inhibidores de cinasas jano. - Google Patents

Derivados heterociclicos como inhibidores de cinasas jano.

Info

Publication number
MX2023010083A
MX2023010083A MX2023010083A MX2023010083A MX2023010083A MX 2023010083 A MX2023010083 A MX 2023010083A MX 2023010083 A MX2023010083 A MX 2023010083A MX 2023010083 A MX2023010083 A MX 2023010083A MX 2023010083 A MX2023010083 A MX 2023010083A
Authority
MX
Mexico
Prior art keywords
compounds
kinase inhibitors
janus kinase
heterocyclic derivatives
treatment
Prior art date
Application number
MX2023010083A
Other languages
English (en)
Inventor
Andrea Rizzi
Fabio Rancati
Alessandro Accetta
Alberto Cuzzolin
Milan Mesic
Dinko Ziher
Ivaylo Elenkov
Rahela Zadravec
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2023010083A publication Critical patent/MX2023010083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula general (I) que inhiben la familia JAK de tirosina proteína cinasas no receptoras (JAK1, JAK2, JAK3 y TYK2), métodos para preparar estos compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Los compuestos de la invención pueden ser útiles en el tratamiento de enfermedades o condiciones asociadas con una desregulación de las cinasas no receptoras de la familia JAK; en particular para el tratamiento de varias enfermedades inflamatorias que incluyen asma, COPD y otras enfermedades respiratorias.
MX2023010083A 2021-03-15 2022-03-14 Derivados heterociclicos como inhibidores de cinasas jano. MX2023010083A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21162515 2021-03-15
EP21217274 2021-12-23
PCT/EP2022/056548 WO2022194779A1 (en) 2021-03-15 2022-03-14 Heterocyclic derivatives as janus kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2023010083A true MX2023010083A (es) 2023-09-07

Family

ID=80999796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010083A MX2023010083A (es) 2021-03-15 2022-03-14 Derivados heterociclicos como inhibidores de cinasas jano.

Country Status (8)

Country Link
US (1) US20240279240A1 (es)
EP (1) EP4308122A1 (es)
JP (1) JP2024510246A (es)
KR (1) KR20230157431A (es)
AU (1) AU2022239752A1 (es)
CA (1) CA3211575A1 (es)
MX (1) MX2023010083A (es)
WO (1) WO2022194779A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4308244A1 (en) * 2021-03-15 2024-01-24 Chiesi Farmaceutici S.p.A. Heterocyclic derivatives as janus kinase inhibitors
AU2023336560A1 (en) * 2022-09-09 2025-04-17 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
KR20250060914A (ko) * 2022-09-09 2025-05-07 키에시 파르마슈티시 엣스. 피. 에이. 야누스 키나아제 억제제로서 헤테로사이클릭 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP4308244A1 (en) * 2021-03-15 2024-01-24 Chiesi Farmaceutici S.p.A. Heterocyclic derivatives as janus kinase inhibitors

Also Published As

Publication number Publication date
CA3211575A1 (en) 2022-09-22
JP2024510246A (ja) 2024-03-06
WO2022194779A1 (en) 2022-09-22
AU2022239752A1 (en) 2023-10-26
KR20230157431A (ko) 2023-11-16
US20240279240A1 (en) 2024-08-22
EP4308122A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.
MX2023010083A (es) Derivados heterociclicos como inhibidores de cinasas jano.
PH12021552885A1 (en) Nlrp3 inflammasome inhibitors
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
JP5409783B2 (ja) 置換ｎ−オキシドピラジン誘導体
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
WO2010011375A3 (en) Inhibitors of janus kinases
NO20064046L (no) Pyrazolpyrimidinderivater som syklinavhengige kinaseinhibitorer
NO20084997L (no) Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer
MX2009013218A (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus.
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
WO2007061764A3 (en) Tricyclic compounds useful as inhibitors of kinases
MX2009002657A (es) Derivados dibenzofurano como inhibidores de pde-4 y pde-10.
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
GB0112348D0 (en) Compounds
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
GB201302704D0 (en) Therapeutic compounds
NZ598144A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof